This website has been developed by Besins Healthcare (UK) Ltd. This website has separate sections for healthcare professionals and patients who have been prescribed Testogel® 16.2 mg/g gel, within the UK.

Besins Healthcare is a pharmaceutical company specialising in the development of innovative drugs for the well-being of men and women throughout their life.

This website is provided for HCPs in the UK by Besins Healthcare (UK) Ltd.

Testicular cancer

Kim beat testicular cancer.

Now he needs a treatment

that can protect him from

the long-term consequences

of testosterone deficiency.

Kim, aged 38

Kim - cancer treatment
treat me

Patient profile is fictional and for illustrative purposes only.

Treatment

Testosterone therapy can reduce the risk of long-term adverse metabolic and cardiovascular impact in patients with testosterone deficiency (TD).1-3†

In a 6-month double-blind randomised placebo-controlled trial of young male cancer survivors (TRYMS study), testosterone therapy was associated with significant improvement in body composition in testicular cancer survivors vs. placebo at 26 weeks.3

Graph

Boxes represent the interquartile range, circles indicate the mean, lines inside the box indicate the median, whiskers represent the range excluding outliers, and asterisks indicate outliers.

Adapted from Walsh JS, et al. 2019.

The active treatment in the above study was testosterone 2% gel (Kyowa Kirin).
The studies include data on patients receiving a range of testosterone therapies including gels.

Significantly reduce trunk fat mass
Significantly reduce whole body fat mass
Significantly increase body lean mass

Obesity, diabetes, metabolic syndrome and cardiovascular disease are closely related conditions that all have negative long-term health effects.4-6

Testosterone therapy with Testogel®
16.2 mg/g gel may help protect your patients

from the long-term consequences of TD.3

Testogel pack

Request more information

If you would like to discover more about how Testogel® 16.2 mg/g gel can help your patients, please complete a request form.

References

  1. Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36(40):2706–2715.
  2. IJpma I, Renken RJ, Gietema JA, et al. Taste and smell function in testicular cancer survivors treated with cisplatin-based chemotherapy in relation to dietary intake, food preference, and body composition. Appetite. 2016;105:392–399.
  3. Walsh JS, Marshall H, Smith IL, et al. Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial. PLoS Med. 2019;16(11):e1002960.
  4. Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18(1):5–15.
  5. Hackett G, Kirby M, Edwards D, et al. UK policy statements on testosterone deficiency. Int J Clin Pract. 2017;71:3–4.
  6. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004;89(6):2595–2600.

TES/2020/009. April 2021.

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: pharmacovigilance@besins-healthcare.com